- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04383015
Carbohydrate and Insulin Requirements During Prolonged Fasted Exercise
Carbohydrate Requirements for Prolonged, Fasted Exercise With and Without Basal Rate Reductions in Individuals With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion
Studieoversigt
Detaljeret beskrivelse
This project focuses on the effectiveness of various exercise strategies on the time spent in target range during and after aerobic exercise in adults with type 1 diabetes (T1D) on continuous subcutaneous insulin infusion (CSII).
The primary objective of the protocol is to determine if a moderate basal insulin reduction (-50 percent of basal), performed 90-minutes before a 120-minute aerobic exercise session (with 5-minute breaks every 30 minutes of exercise, and a ten minute break mid-exercise), improves the time in target range compared to either a carbohydrate consumption only strategy or insulin reduction (-50 percent) and carbohydrate consumption strategy both performed at the onset of exercise in patients with T1D on CSII therapy. The time in target will be determined for both the exercise period and during a 24-hour window after the end of exercise.
In all three sessions, aerobic exercise (brisk walking) will be performed in the fasted state (minimum 8 hours after the last meal) in the early-morning. The exercise will consist of four 30-minute bouts of walking at 40-50 percent of the participant's pre-determined aerobic capacity, separated by 5-10 minute breaks. The participants exercise intensity will be monitored continuously using heart rate and activity monitors. Blood glucose and blood ketone levels will be monitored throughout exercise.
Each participant will be assigned to a sequence of the three experimental visits through a randomization process. Each exercise session will be separated by at least two days and participants will be expected to complete all sessions within ~ 12 weeks from the time of the baseline/screening visit. Participants will be instructed to apply a new continuous glucose monitor (CGM) sensor between 1-5 days prior, not to perform moderate-to-vigorous exercise 24 hours prior and refrain from caffeine and alcohol 12 hours prior to each study visit. Participants are also instructed not to eat after 2330h the night before arriving to the laboratory and not to give bolus insulin or perform temporary basal rate changes after 0200h on the morning of the exercise visit. Participants are instructed to try to arrive at the laboratory with their blood glucose between 72-270 mg/dL, with no active bolus insulin according to personal CSII device, in the fasted state. If a bolus of insulin was given prior to the exercise session, the session was rescheduled. Females of reproductive capacity performed all three visits in the early follicular phase (days 1-6 of cycle). Participants arrived at the laboratory between 0600h and 1000h. Exercise start time was between 0700h and 1045h, based on participants' choice, and the timing of exercise was kept consistent within participants.
Following each exercise session, the participant will rest for 20-minutes and then leave the laboratory. The participants glucose will be monitored for 24-hours after the standardized exercise. They will also be instructed to perform a standardized basal insulin reduction overnight to help reduce the risk of post-exercise nocturnal hypoglycemia (-20 percent from bedtime for 6 hours).
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Ontario
-
Toronto, Ontario, Canada, M3J1P3
- York University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Clinical diagnosis of presumed autoimmune type 1 diabetes
- Last HbA1c ≤ 9.9 percent
- Age: 17+ years
- Duration of T1D: ≥ 1.5 years
- Using insulin pump therapy: ≥3 months (at least 0.25 units of insulin per kilogram of body mass)
- In good general health with no conditions that could impact the outcome of the trial
- Willing to adhere to the protocol requirements for the duration of the study
Exclusion Criteria:
- Physician diagnosis of active diabetic retinopathy that could be worsened by exercise
- Physician diagnosis of peripheral neuropathy or autonomic neuropathy
Medications:
- Beta-blockers
- Agents that affect hepatic glucose production (xanthine derivatives)
- Pramlintide
- Any other hypoglycemic agent
- Participation in other studies involving the administration of an investigational drug or device during the duration of the current study
- Severe hypoglycemia in the last 3 months, defined as the individual requiring third party assistance or hospitalization
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Crossover opgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Carbohydrate (CHO)-only
Carbohydrate dose of 0.3g/kg/hr given every 30 minutes of exercise if blood glucose is in range with usual basal insulin infusion
|
Strategies for exercise in type 1 diabetes to maintain glucose control
|
Andet: 50 Percent Basal Rate Reduction (BRR)
A 50 percent basal rate reduction set 90-minutes pre-exercise and throughout exercise
|
Strategies for exercise in type 1 diabetes to maintain glucose control
|
Andet: Combo
The combination of a 50 percent basal rate reduction and carbohydrate dose of 0.3g/kg/hr (given every 30 minutes) both at exercise onset
|
Strategies for exercise in type 1 diabetes to maintain glucose control
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Time in glucose target range during exercise intervention
Tidsramme: 140 minutes
|
The primary outcome measurement is to determine which strategy had the best time in blood glucose target range (4.0-10.0
mmol/L) during the prolonged exercise
|
140 minutes
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Recovery Interstitial Glucose
Tidsramme: 24 hours
|
Using CGM to measure recovery glucose levels post-exercise to analyze time in target range, time in hypoglycemia (< 4.0 mmol/L) and time in hyperglycemia (> 10.0 mmol/L).
|
24 hours
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Michael Riddell, PhD, York University
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- e2018-306
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordAfsluttetFysisk aktivitet | Mental sundhed velvære 1 | Kognitiv funktion 1, Social | Academic Attainment | Fitness TestingDet Forenede Kongerige
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekræft | Faste tumorer | Programmeret celledød-1 (PD1, PD-1) | Programmeret celledød 1 Ligand 1 (PDL1, PD-L1) | Programmeret celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
SanionaAfsluttet
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionAfsluttet
-
Calliditas Therapeutics ABAfsluttet
-
Alvotech Swiss AGAfsluttet
-
PfizerAfsluttet
-
Stony Brook UniversityAfsluttet
-
JKT Biopharma Co., Ltd.Rekruttering
-
Graviton Bioscience CorporationAfsluttet
Kliniske forsøg med Exercise strategies
-
Hospices Civils de LyonIkke rekrutterer endnu
-
China National Center for Cardiovascular DiseasesUkendt
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceAfsluttet
-
Wuhan Asia Heart HospitalIkke rekrutterer endnuKoronararteriesygdom | ST Elevation Myokardieinfarkt
-
University Hospital, AngersRekruttering
-
RTI InternationalNational Institute on Drug Abuse (NIDA)Afsluttet
-
KCRISIS Medical AGAfsluttetKoronararteriesygdom | Angina, stabil | Angina, ustabilSchweiz
-
First Affiliated Hospital Xi'an Jiaotong UniversityRekrutteringSlag | Rehabilitering | Gentagen transkraniel magnetisk stimulering | Funktionel nær-infrarød spektroskopiKina
-
Universita di VeronaRekruttering
-
University Hospital, MontpellierAfsluttet